<DOC>
	<DOCNO>NCT00061126</DOCNO>
	<brief_summary>A clinical trial examine safety effectiveness ABX-EGF give patient prostate cancer without tumor part body . Patients treat maximum 48 dos ( 6 treatment course ; 8 dos per course ) evidence progressive disease .</brief_summary>
	<brief_title>ABX-EGF ( Monoclonal Antibody ) Given Patients With Prostate Cancer With Without Tumor Other Parts Body</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 year age older Has tumor tissue available diagnostics Failed front line luteinizing hormonereleasing hormone analogue ( LHRH ) leuprolide goserelin , fail orchiectomy , evidence disease progression . Patients must continue LHRH analogue ( unless patient orchiectomy ) throughout course study ECOG score 0 1 Any prior chemotherapy prostate cancer besides hormonal therapy ( include prior EGFr target agent ) Prior history cancer prostate carcinoma within past 5 year require treatment active ( prior basal cell carcinoma allow ) Known HIV positive Myocardial infarction within one year prior enter study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>PSA</keyword>
	<keyword>Hormone refractory</keyword>
	<keyword>Rising PSA</keyword>
</DOC>